PubRank

N S Key

Author PubWeight™ 57.19‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Guidelines for the management of hemophilia. Haemophilia 2012 5.16
2 Measuring circulating cell-derived microparticles. J Thromb Haemost 2004 2.61
3 C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993 2.48
4 Hypotensive reactions to white cell-reduced plasma in a patient undergoing angiotensin-converting enzyme inhibitor therapy. Transfusion 1996 2.22
5 Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2010 2.12
6 Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest 1998 1.58
7 Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2013 1.53
8 Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest 1993 1.45
9 Polymorphism in the tissue factor region is associated with basal but not endotoxin-induced tissue factor-mRNA levels in leukocytes. J Thromb Haemost 2006 1.43
10 Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J Thromb Haemost 2006 1.33
11 Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 2012 1.29
12 Iliofemoral deep venous thrombosis: safety and efficacy outcome during 5 years of catheter-directed thrombolytic therapy. J Vasc Interv Radiol 1997 1.29
13 Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. Thromb Res 2011 1.25
14 The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. J Thromb Haemost 2007 1.16
15 Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014 1.09
16 Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999 1.08
17 Prospective study of sickle cell trait and venous thromboembolism incidence. J Thromb Haemost 2014 1.08
18 Challenges of rare disease research: limited patients and competing priorities. Haemophilia 2011 0.94
19 Racial differences in endotoxin-induced tissue factor-triggered coagulation. J Thromb Haemost 2009 0.93
20 Venous thromboembolism in malignant gliomas. J Thromb Haemost 2009 0.92
21 Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000 0.92
22 In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost 2010 0.91
23 Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia 2012 0.91
24 Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia 2012 0.91
25 The contribution of red blood cells to thrombin generation in sickle cell disease: meizothrombin generation on sickled red blood cells. J Thromb Haemost 2013 0.88
26 CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Thromb Haemost 1999 0.87
27 Iliopsoas haemorrhage in patients with bleeding disorders--experience from one centre. Haemophilia 2003 0.86
28 Single-center experience with rituximab as first-line immunosuppression for acquired hemophilia. J Thromb Haemost 2011 0.85
29 Pilot study to test the efficacy and safety of activated recombinant factor VII (NovoSeven) in the treatment of refractory hemorrhagic cystitis following high-dose chemotherapy. Bone Marrow Transplant 2006 0.83
30 Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria. Atherosclerosis 1996 0.83
31 Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C. A potential mechanism for enhancing generation of activated protein C. J Biol Chem 1997 0.83
32 Platelet factor 4 stimulates thrombomodulin protein C-activating cofactor activity. A structure-function analysis. J Biol Chem 1994 0.83
33 Factor VIII inhibitory antibody in a patient with combined factor V/factor VIII deficiency. Haemophilia 2014 0.82
34 Acquired factor VII deficiency in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2002 0.82
35 CD4+ T cells specific for factor VIII as a target for specific suppression of inhibitor production. Adv Exp Med Biol 2001 0.80
36 Whole blood tissue factor procoagulant activity remains detectable during severe aplasia following bone marrow and peripheral blood stem cell transplantation. Thromb Haemost 2001 0.79
37 Prothrombotic phenotype diversity of human aortic endothelial cells in culture. Thromb Res 1992 0.79
38 Herpes virus infection of endothelium: new insights into atherosclerosis. Trans Am Clin Climatol Assoc 1992 0.79
39 Clinical features and management of haemophilic pseudotumours: a single US centre experience over a 30-year period. Haemophilia 2013 0.79
40 Induction of tissue factor procoagulant activity in myelomonocytic cells inoculated by the agent of human granulocytic ehrlichiosis. Thromb Haemost 2000 0.77
41 Successful liver transplantation in a patient with severe haemophilia A and a high-titre factor VIII inhibitor. Haemophilia 2004 0.77
42 Scratching the surface: endothelium as a regulator of thrombosis, fibrinolysis, and inflammation. J Lab Clin Med 1992 0.77
43 Characterization of an apparently synonymous F5 mutation causing aberrant splicing and factor V deficiency. Haemophilia 2014 0.76
44 Circulating anticoagulant glycosaminoglycans in mucopolysaccharidosis type I. J Thromb Haemost 2008 0.76
45 Septic arthritis in males with haemophilia. Haemophilia 2008 0.76
46 Rituximab for treatment of inhibitors in haemophilia A. A Phase II study. Thromb Haemost 2014 0.76
47 Potential biomarkers of an exaggerated response to endotoxemia. Biomarkers 2007 0.76
48 Molecular unraveling of von Willebrand's disease: still some way to go. J Lab Clin Med 1997 0.75
49 Toward an understanding of the pathophysiologic mechanism of thrombosis in the antiphospholipid antibody syndrome. J Lab Clin Med 1995 0.75
50 More on: intensity of warfarin anticoagulation in APS. J Thromb Haemost 2005 0.75
51 Novel inherited risk factors for venous thrombosis. J Lab Clin Med 1998 0.75
52 Simultaneous occurrence of posttransfusion purpura due to anti-HPA-1a and a delayed transfusion reaction due to anti-Jk(b) Transfusion 1997 0.75
53 Rituximab as first-line treatment for the management of adult patients with non-severe hemophilia A and inhibitors. J Thromb Haemost 2014 0.75
54 Joint WFH-ISTH session: issues in clinical trial design. Haemophilia 2014 0.75
55 Thrombotic stroke associated with the use of porcine factor VIII in a patient with acquired haemophilia. Haemophilia 2002 0.75
56 Interferon-alpha restores beta1-integrin-dependent, collagen-mediated platelet aggregation in a patient with chronic myelogenous leukemia. J Lab Clin Med 1998 0.75
57 Detection of the factor VLeiden mutation. Development of a testing algorithm combining a coagulation assay and molecular diagnosis. Am J Clin Pathol 1997 0.75
58 Venous thrombosis prophylaxis in haemophilics undergoing major orthopaedic surgery: a survey of haemophilia treatment centres. Haemophilia 2009 0.75
59 Patient/caregiver assessment of convenience in the use of recombinant activated factor VII (rVIIa; NovoSeven) in home therapy. Blood Coagul Fibrinolysis 2000 0.75
60 Serologic evidence that factor IX inhibitor in the plasma of hemophilia B patients detects factor IX on normal red cells. Transfusion 1996 0.75